J Clin Oncol 2012; 30: 4297–4301. 52 Alfa-Wali M, Allen-Mersh T, Antoniou A et al. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann Oncol 2012; 23: 141–147. 53 Mistrangelo M, Conte ID, Cassoni P et al. Anal cancer: differences between HIV+ and HIV- patients. Colorectal Dis 2011; 13: 20. 54 Takahashi T, Braghiroli MI, Souza CE et al. Concurrent chemoradiation as definitive treatment in anal squamous cell carcinoma – Efficacy and safety PS 341 in HIV+

patients under HAART. Eur J Cancer 2011; 47: S448. 55 Salama JK, Mell LK, Schomas DA et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. [Erratum appears in J Clin Oncol 2008; 26: 694]. J Clin Oncol 2007; 25: 4581–4586. 56 DeFoe SG, Beriwal S, Jones H et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma–clinical

GSK3 inhibitor outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol) 2012; 24: 424–431. 57 Azria D, Vieillot S, Lemanski C et al. Clinical outcome of patients treated with IMRT for locally advanced anal canal cancer. Int J Radiat Oncol Biol Phys 2011; 81: S377. 58 Kachnic LA, Tsai HK, Coen JJ et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012; 82: 153–158. 59 Hoffman R, Welton ML, Klencke B et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999; 44: 127–131. 60 Peddada AV, Smith DE, Rao Fossariinae AR et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1997; 37: 1101–1105. 61 Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum 2001; 44: 506–512. 62 Blazy A, Hennequin

C, Gornet JM et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 2005; 48: 1176–1181. 63 Wexler A, Berson AM, Goldstone SE et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008; 51: 73–81. 64 Fraunholz I, Weiss C, Eberlein K et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys 2010; 76: 1425–1432. 65 Ajani JA, Winter KA, Gunderson LL et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.